John Slattery, MD
Family Medicine · East Greenwich, RINPI 1033109236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $959, 2.1 times the $460 reported in 2019.
Across 185 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$876
- Novo Nordisk$479
- GSK$423
- Lilly USA, LLC$290
- AbbVie$209
- Exact Sciences$203
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,64799%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $876 |
| Novo Nordisk | 25 | $479 |
| GSK | 23 | $423 |
| Lilly USA, LLC | 14 | $290 |
| AbbVie(2 entities) | 10 | $209 |
| Exact Sciences | 8 | $203 |
| Boehringer Ingelheim | 13 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $171 |
| Phathom Pharmaceuticals, Inc. | 5 | $164 |
| Pfizer | 7 | $131 |
| Jazz Pharmaceuticals Inc. | 6 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $91 |
| Biohaven Pharmaceuticals, Inc. | 4 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $56 |
| Bausch Health US, LLC | 3 | $55 |
| Amgen | 2 | $35 |
| Abbott | 1 | $25 |
| Shire North American Group Inc | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
How this compares
$3,675 in reported general payments places this provider in the 85th percentile of 222 family medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $40,590 |
| EliquisApixaban | 43 | $40,301 |
| XareltoRivaroxaban | 19 | $28,621 |
| JardianceEmpagliflozin | 26 | $25,959 |
| Xtampza ErOxycodone Myristate | 25 | $25,262 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $21,937 |
| Repatha SureclickEvolocumab | 16 | $18,694 |
| InvokanaCanagliflozin | 12 | $6,789 |
| CreonLipase/Protease/Amylase | 18 | $5,925 |
| Bupropion XlBupropion Hcl | 15 | $5,618 |
| Rosuvastatin Calcium | 165 | $2,433 |
| Ventolin HfaAlbuterol Sulfate | 33 | $2,155 |
| AtacandCandesartan Cilexetil | 12 | $1,889 |
| Atorvastatin Calcium | 146 | $1,652 |
| Levothyroxine Sodium | 149 | $1,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $479 | $40,59042 claims |
| PfizerEliquis | $131 | $40,30143 claims |
| Boehringer IngelheimJardiance | $175 | $25,95926 claims |
| GSKTrelegy Ellipta | $423 | $21,93715 claims |
| AbbVieCreon | $209 | $5,92518 claims |
| AstraZenecaAtacand | $876 | $1,88912 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $1,638149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 family medicine providers in Rhode Island.
Other family medicine in East Greenwich
- Pierre ManzoEast Greenwich$5K
- Ellen HightEast Greenwich$4K
- Lauren GoddardEast Greenwich$737
- Gina la ProvaCumberland$778K
- Wilfredo Giordano-PerezJohnston$351K
- Martin MinerProvidence$124K
- Frank la FaziaWest Warwick$19K
- Jamiel AmbradWakefield$18K
- Jason AustinJohnston$15K
- Mary SutterPawtucket$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.